During the first 18 months, the UltraSense project has made substantial progress in establishing the scientific, technological, and organizational foundations required to deliver its advanced multimodal sensing platform. The work performed has progressed in line with the planned timeline, with several key work packages successfully completed and others advancing according to expectations.
At the outset, WP1 defined the project’s technical baseline by establishing use-case requirements, system and component specifications, and material and biofunctionalization protocols for the G-FET biosensing platform. In parallel, regulatory considerations and Life Cycle Assessment (LCA) scope were addressed, ensuring early alignment with standards and sustainability objectives. This foundational work enabled a coherent and structured transition into technology development activities.
Building on these specifications, WP2 successfully developed the advanced materials underpinning the UltraSense platform. High-quality graphene tailored for Laser-Induced Forward Transfer (LIFT), alongside optimized silver and gold nanoparticle inks and selected bioreagents, were delivered and validated. These results provide a complete material toolkit that directly supports device fabrication and integration.
Following this, WP3 was initiated to upscale material processes toward industrial relevance. Early activities have focused on transitioning graphene synthesis to wafer-scale production and optimizing nanoparticle-based inks for scalable LIFT processing. Strong coordination among partners has been established, laying the groundwork for industrial-grade validation in the next phase.
In parallel, WP4 has established the data infrastructure and initiated AI model development. A unified metadata and versioning framework has been deployed across the consortium, ensuring robust and traceable data handling. Initial benchmarking and model development activities are underway, with a focus on probabilistic multimodal data fusion approaches that will support advanced sensing capabilities.
On the device side, WP6 has been successfully completed, delivering the full design of the three core sensor compartments: ultrasound (PMUT-based), bioimpedance, and G-FET biosensing. These designs are fully aligned with system-level requirements and integration constraints. Building on this, WP7 has commenced and is progressing well, focusing on translating designs into fabrication-ready prototypes and establishing development pipelines for subsequent testing and validation.
Complementing the technical work, WP12 ensured effective dissemination, communication, and initial exploitation planning. The project has established a strong external presence through its website, publications, and participation in key events, while structured IP monitoring and market analysis activities have laid the foundation for future exploitation.
Finally, WP15 has provided robust project management and scientific coordination, ensuring timely execution, effective risk management, and compliance with administrative, legal, and data governance requirements. Engagement with an External Advisory Board has further strengthened strategic alignment and validated project progress.
Overall, the project is progressing according to plan, with all completed work packages delivering their expected outcomes and ongoing activities advancing steadily. UltraSense is now well positioned to enter its next phase, focusing on material upscaling, device fabrication, system integration, and data-driven validation of its sensing technologies.
